Archive
Every story, newest first.
Tuesday, October 27, 2026
Rates
Euro area banks tightened firm credit standards by a net 9 percent in the ECB survey, Italy auctions up to 3.5 billion euros of BTPs on October 27, and official auctions and operations across India and Japan filled the week's funding calendar.
Rates
Japan's Ministry of Finance will auction about 250 billion yen of five year Climate Transition JGBs on November 2, maturing September 20, 2031, it announced on October 26.
Rates
The Federal Reserve opens its October 27 to 28 meeting on Tuesday with market pricing favouring no change to the 3.75 to 4.00 percent target range and a hike in December priced as the likelier next move.
Rates
The dollar index rose 0.27 percent to 102.23 in the latest tables, the euro fell 0.66 percent to 1.1143 dollars, and the yen weakened 0.58 percent to 157.74 per dollar.
Commodities
An oil spill from a damaged tanker off the United Arab Emirates has widened toward Umm Al Quwain, Copernicus satellite images dated October 24 showed, prompting more beach closures.
Commodities
Tanker freight rose 4.15 percent while dry bulk fell 2.3 percent in the latest tables, soybeans rose 1.25 percent, and Japan's definitive stainless duties and the IAEA's latest Fukushima water confirmation rounded out the commodity file.
Commodities
Brent crude fell 4.21 percent to 110.93 dollars a barrel in the latest market tables even as Saudi air defences intercepted two drones near the Ras Tanura oil hub.
Infrastructure
Akaysha Energy has refinanced project level debt on four Australian battery projects into a single A$1.75 billion portfolio facility backed by 11 banks, the company announced on October 20, 2026.
Technology
More than $150 million of AI equipment has been stolen in 2026, with fraud behind 92 percent of high value technology shipment thefts analysed, cargo risk firm Overhaul reported, via Datacenter Dynamics.
Life Sciences
Aclaris Therapeutics said on October 27 that its anti-TSLP and IL-4R alpha bispecific antibody ATI-052 met the primary objective in Phase 1b proof of concept trials in atopic dermatitis and asthma, and that it will prioritize Phase 2b development in eosinophilic esophagitis.